Tepanil Ten-Tab, 75 mg, Controlled Release Tablets (Diethylpropion hydrochloride)
Diethylpropion hydrochloride, a sympathomimetic agent.
Diethylpropion hydrochloride tablets are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regiment of weight reduction based on caloric restriction. The usefulness of agents of this class should be measured against possible risk factors inherent in their use such as those described (see CLINICAL PHARMACOLOGY).
Published Studies Related to Tepanil (Diethylpropion)
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. [2009.08]
OBJECTIVE: To evaluate the efficacy of diethylpropion on a long-term basis, with emphasis in cardiovascular and psychiatric safety aspects... CONCLUSION: Diethylpropion plus diet produced sustained and clinically significant weight loss over 1 year. It seems to be safe in relation to cardiovascular and psychiatric aspects in a well-selected population.
Clinical Trials Related to Tepanil (Diethylpropion)
LOSS- Louisiana Obese Subjects Study [Terminated]
LOSS is a pragmatic clinical evaluation of intensive medical approaches to weight loss for
individuals with extreme obesity (body mass index [BMI] 40-60 kg/m2). The intensive medical
treatment is designed to produce 25% weight loss from baseline and to maintain at least 20%
weight loss from baseline. The intensive medical treatment is compared to a usual care
treatment model where individuals utilize self directed approaches to weight loss. The
active treatment period is three years, followed by two years of observation.
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse [Completed]
This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to
learn if NRP104 produces a high and any other effects like amphetamine and other stimulant
drugs that are abused. This information will give some indication if NRP104 can be abused.
NRP104 is an investigational drug. This means that it has not been approved by the U. S.
Food and Drug Administration (FDA). Healthy people, between the ages of 18 and 55 with
histories of substance abuse that include stimulant drugs, may join. Amphetamines are drugs
that are used most often to treat attention deficit hyperactivity disorder (ADHD) in
children, to treat narcolepsy (excessive sleepiness) and for weight loss.
PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011 [Active, not recruiting]
Bupropion hydrochloride was first approved on 30 December 1985 in United States for
depression and is currently approved in 80 countries. Bupropion has also subsequently been
approved for smoking cessation and for seasonal affective disorder.
Cumulative exposure to bupropion is estimated at approximately 97. 3 million patient
exposures up to 31 December 2012.
Bupropion hydrochloride is a weak catecholamine reuptake inhibitor predominantly affecting
serotonin, norepinephrine and dopamine. Its mechanism of action and its structural
similarities to diethylpropion, amphetamines, and cocaine, bupropion resembles stimulants in
many respects, leading to concerns about potential abuse of the product.
Abuse potential had been part of the Benefit Risk Management Plan for bupropion up until
2003 and at that point, had no longer been regarded as a potential risk that required
additional/further evaluation outside standard pharmacovigilance monitoring. The current
European Risk Management Plan also states that standard pharmacovigilance monitoring applies
to abuse potential. Monitoring has shown a recent increase in the number of spontaneous
reports from the Adverse Event reporting System (AERS) of drug abuse.
The bupropion team agreed that although the numbers of abuse reports was small relative to
the total number of reports for bupropion in OCEANS, there was sufficient information in
AERS to warrant investigation of the potential effect on public health.
To investigate the degree of misuse and abuse of bupropion (including non-oral routes of
administration) in the United States, the Drug Abuse Warning Network will be used to examine
the study period 2004-2011.
Page last updated: 2009-10-20